Comment
doi: 10.1016/S1470-2045(23)00014-1.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer
Affiliations
- PMID: 36858724
- DOI: 10.1016/S1470-2045(23)00014-1
Item in Clipboard
Comment
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer
Lancet Oncol.
2023 Mar.
No abstract available
Conflict of interest statement
HI reports receiving consulting fees from Chugai, AstraZeneca, Lilly, Pfizer, Daiichi-Sankyo, and Kyowa Hakko Kirin. KN and MS declare no competing interests.
Comment in
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.Lancet Oncol. 2023 Mar;24(3):e104. doi: 10.1016/S1470-2045(23)00065-7. Lancet Oncol. 2023. PMID: 36858725 No abstract available.
Comment on
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
